Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms.

Wang J, Xu Z, Liu L, Gale RP, Cross NC, Jones AV, Qin T, Ai X, Xu J, Zhang T, Sun X, Li Q, Zhang P, Zhang Y, Xiao Z.

Leukemia. 2013 Aug;27(8):1763-7. doi: 10.1038/leu.2013.21. Epub 2013 Jan 22. No abstract available.

PMID:
23337930
2.

The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms.

Trifa AP, Cucuianu A, Petrov L, Urian L, Militaru MS, Dima D, Pop IV, Popp RA.

Ann Hematol. 2010 Oct;89(10):979-83. doi: 10.1007/s00277-010-0960-y. Epub 2010 Apr 27.

PMID:
20422415
3.

MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms.

Patnaik MM, Lasho TL, Finke CM, Gangat N, Caramazza D, Siragusa S, Hanson CA, Pardanani A, Tefferi A.

Leukemia. 2010 Apr;24(4):859-60. doi: 10.1038/leu.2010.1. Epub 2010 Jan 28. No abstract available.

PMID:
20111067
4.

Genetic association between germline JAK2 polymorphisms and myeloproliferative neoplasms in Hong Kong Chinese population: a case-control study.

Koh SP, Yip SP, Lee KK, Chan CC, Lau SM, Kho CS, Lau CK, Lin SY, Lau YM, Wong LG, Au KL, Wong KF, Chu RW, Yu PH, Chow EY, Leung KF, Tsoi WC, Yung BY.

BMC Genet. 2014 Dec 20;15:147. doi: 10.1186/s12863-014-0147-y.

5.

The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.

Ohyashiki JH, Yoneta M, Hisatomi H, Iwabuchi T, Umezu T, Ohyashiki K.

BMC Med Genet. 2012 Jan 17;13:6. doi: 10.1186/1471-2350-13-6.

6.

Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis.

Lippert E, Mansier O, Migeon M, Denys B, Nilsson A, Rosmond C, Lodé L, Ugo V, Lascaux A, Bellosillo B, Martinez-Lopez J, Naguib D, Gachard N, Maroc N, Hermouet S.

Haematologica. 2014 Jul;99(7):e98-101. doi: 10.3324/haematol.2014.107656. Epub 2014 May 16. No abstract available.

7.

The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms.

Soler G, Bernal-Vicente A, Antón AI, Torregrosa JM, Caparrós-Pérez E, Sánchez-Serrano I, Martínez-Pérez A, Sánchez-Vega B, Vicente V, Ferrer-Marin F.

Ann Hematol. 2015 May;94(5):789-94. doi: 10.1007/s00277-014-2266-y. Epub 2014 Dec 9.

PMID:
25482455
8.

JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.

Pietra D, Casetti I, Da Vià MC, Elena C, Milanesi C, Rumi E.

Am J Hematol. 2012 Jul;87(7):746-7. doi: 10.1002/ajh.23229. Epub 2012 May 6.

9.

JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia.

Andrikovics H, Nahajevszky S, Koszarska M, Meggyesi N, Bors A, Halm G, Lueff S, Lovas N, Matrai Z, Csomor J, Rasonyi R, Egyed M, Varkonyi J, Mikala G, Sipos A, Kozma A, Adam E, Fekete S, Masszi T, Tordai A.

Leukemia. 2010 Oct;24(10):1809-13. doi: 10.1038/leu.2010.172. Epub 2010 Sep 2. No abstract available.

PMID:
20811399
10.

JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan.

Edahiro Y, Morishita S, Takahashi K, Hironaka Y, Yahata Y, Sunami Y, Shirane S, Tsutsui M, Noguchi M, Koike M, Imai K, Kirito K, Noda N, Sekiguchi Y, Tsuneda S, Ohsaka A, Araki M, Komatsu N.

Int J Hematol. 2014;99(5):625-34. doi: 10.1007/s12185-014-1567-1. Epub 2014 Mar 28.

PMID:
24677207
11.

[Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].

Zhang Y, Li L, Nie L, Yu Y, Yang YH, Zhang ZQ, Yang L, Xu SC, Xiao ZJ.

Zhonghua Xue Ye Xue Za Zhi. 2008 Feb;29(2):105-9. Chinese.

PMID:
18681311
12.

Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms.

Alvarez-Larrán A, Angona A, Martínez-Avilés L, Bellosillo B, Besses C.

Leuk Res. 2012 Mar;36(3):324-6. doi: 10.1016/j.leukres.2011.09.029. Epub 2011 Oct 15.

PMID:
22001278
13.

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.

Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A.

Leukemia. 2008 Jul;22(7):1299-307. doi: 10.1038/leu.2008.113. Epub 2008 May 22. Review.

PMID:
18496562
14.

JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients.

Tanaka M, Yujiri T, Ito S, Okayama N, Takahashi T, Shinohara K, Azuno Y, Nawata R, Hinoda Y, Tanizawa Y.

Int J Hematol. 2013 Mar;97(3):409-13. doi: 10.1007/s12185-013-1295-y. Epub 2013 Feb 22.

PMID:
23430670
15.

JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms.

Villani L, Bergamaschi G, Primignani M, Rosti V, Carolei A, Poletto V, Catarsi P, Spolverini A, Vannucchi AM, Barosi G.

Leuk Res. 2012 Jan;36(1):e7-9. doi: 10.1016/j.leukres.2011.08.008. Epub 2011 Sep 3. No abstract available.

PMID:
21890200
16.

Extinction of myeloproliferative neoplasm by acquisition of a lymphoid disease: JAK2 (V617F) and JAK2 exon 12 allele burden disappearance during the follow-up of two patients.

Mahé K, Luque Paz D, Couturier MA, Chauveau A, Quintin-Roué I, Berthou C, Ugo V, Lippert E, Ianotto JC.

Ann Hematol. 2016 Feb;95(3):529-31. doi: 10.1007/s00277-015-2559-9. Epub 2015 Nov 27. No abstract available.

PMID:
26611851
17.

Single nucleotide polymorphism (SNP)-based loss of heterozygosity (LOH) testing by real time PCR in patients suspect of myeloproliferative disease.

Huijsmans CJ, Poodt J, Damen J, van der Linden JC, Savelkoul PH, Pruijt JF, Hilbink M, Hermans MH.

PLoS One. 2012;7(7):e38362. doi: 10.1371/journal.pone.0038362. Epub 2012 Jul 2.

18.

The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients.

Zhang X, Hu T, Wu Z, Kang Z, Liu W, Guan M.

Int J Hematol. 2012 Nov;96(5):611-6. doi: 10.1007/s12185-012-1169-8. Epub 2012 Sep 29.

PMID:
23054641
19.

A novel, highly sensitive and rapid allele-specific loop-mediated amplification assay for the detection of the JAK2V617F mutation in chronic myeloproliferative neoplasms.

Minnucci G, Amicarelli G, Salmoiraghi S, Spinelli O, Guinea Montalvo ML, Giussani U, Adlerstein D, Rambaldi A.

Haematologica. 2012 Sep;97(9):1394-400. doi: 10.3324/haematol.2011.056184. Epub 2012 Feb 7.

20.

[The discovery of JAK2 mutation has changed the diagnostic criteria of myeloproliferative neoplasms].

Zhu P.

Zhonghua Yi Xue Za Zhi. 2008 Jul 1;88(25):1729-31. Chinese. No abstract available.

PMID:
19035079

Supplemental Content

Support Center